A Small Number of Drugs Account for a Large Share of Medicare Part D Spending
The Inflation Reduction Act requires the federal government to negotiate the price of certain high-spending drugs covered by Medicare. This analysis provides context for understanding the potential impact of negotiating prices for a limited number of Medicare-covered drugs by identifying the 10 top-selling Part D drugs in 2021, measuring the share of total Part D drug spending accounted for by top-selling drugs that year, and examining changes in spending and use of these drugs since 2018.
Lantus Solostar Novo Nordisk Medicare Drug Price Negotiation Program Centers For Medicare Medicaid Service Centers For Medicare Medicaid Services Bristol Myers Squibb
Source: kff.org